Pharming Group's Strategic Financial Maneuver
Pharming Group Lauded for Rare Disease Treatment
Pharming Group to Report First Quarter 2024 Financial Results on May 8
Pharming to Be Honored as Industry Innovator at National Organization for Rare Disorders (NORD) 2024 Rare Impact Awards
Recognition given for achievement in commercializing Joenja (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April
Pharming Group to Buy Back EUR123 Million of Bonds Due 2025
Pharming Group (PHARM.AS) accepted 123.1 million euros of its outstanding 125 million euros of 3% senior unsecured convertible bonds due 2025 for repurchase. The Dutch biopharmaceutical company said A
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds
Pharming Group (PHARM.AS) on Thursday launched an offering of 100 million euros of senior unsecured convertible bonds due 2029 and a repurchase offer for its outstanding 125 million euros of convertib
Optimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market Expansion
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of Its Treatment for Rare Auto-Immune Disorder
Pharming Group (PHAR) said Monday it has finished enrolling 21 patients in a phase 3 clinical trial to evaluate leniolisib as a potential treatment for children aged four to 11 years old with activate
Reported Earlier, Pharming Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib
Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug lenioli
Joenja's Journey: Navigating the Market Risks and Regulatory Challenges Post-Approval for Pharming Group Nv
Pharming Group Files Annual Report, Sets AGM Date
Pharming Group to Participate in April Investor Conferences
Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conferences in the month of April: 23rd Annual
Pharming Group's Strong Performance and Growth Prospects Justify Buy Rating
Pharming Group N.V. (AMS:PHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
Pharming Group Full Year 2023 Earnings: US$0.015 Loss per Share (Vs US$0.021 Profit in FY 2022)
Pharming Reports Q4 Results
Earnings Call Summary | Pharming Group(PHAR.US) Q4 2023 Earnings Conference
The following is a summary of the Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript:Financial Performance:Pharming Group reported an annual revenue of over $227 million for 2023, an increase
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming with a Buy and maintains $37 price target.
Pharming Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 238.83% HC Wainwright & Co. → $37 Reiterates Buy → Buy 08/03/2023 238.83% HC Wainwright & Co. →
Pharming Group's Strong Financial Performance and Growth Potential Merit Buy Rating
No Data